Song Liu1, Jianan Ren, Qiuyuan Xia, Xiuwen Wu, Gang Han, Huajian Ren, Dongsheng Yan, Gefei Wang, Guosheng Gu, Jieshou Li. 1. Medical School of Nanjing University, Departments of General Surgery (SL, JR, XW, HR, DY, GW, GG, JL) and Pathology (QX), Jinling Hospital, Nanjing, China; Department of General Surgery (GH), Second Affiliated Hospital of Jilin University, General Surgery Center of Jilin University, Jilin, China; and Center for the Study of Inflammatory Bowel Disease (SL), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: There are few evidences of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cell (WBC) in differentiating active Crohn's disease (CD) from intestinal lymphoma (IL), intestinal tuberculosis (ITB) and Behcet's syndrome (BD). This study is designed to investigate potential differential capacity of the 3 biomarkers between these disorders. METHODS: A hospital-based case-control study was performed. A total of 29 active CD, 25 IL, 30 ITB and 17 BD patients were collected. Laboratory parameters were drawn from the first blood test results on admission. RESULTS: In active CD group, the level of CRP was 20.2 ± 4.26 mg/dL, which was statistically lower than IL (59.9 ± 10.8 mg/dL, P < 0.0001). Similarly, the level of ESR reached its lowest point in active CD group (23.8 ± 3.18 mm/hr), compared with 46.6 ± 6.46 mm/hr in IL group (P = 0.0002). CRP showed a possible diagnostic value in differentiation of IL from active CD (odds ratio = 1.028, P = 0.046). CRP also exhibited a superior ability (area under curve [AUC] = 0.821) than ESR (AUC = 0.797) and CRP+ESR (AUC = 0.800) in distinguishing active CD from IL. The optimal cutoff value was 19.7 mg/dL, and the sensitivity and specificity were 62.1% and 96.0%, respectively. CONCLUSIONS: A significant decreased level of CRP and ESR was confirmed in active CD compared with IL. Current study demonstrated a possible differential value of CRP between active CD and IL. Further studies would be performed to validate their clinical significances.
BACKGROUND: There are few evidences of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cell (WBC) in differentiating active Crohn's disease (CD) from intestinal lymphoma (IL), intestinal tuberculosis (ITB) and Behcet's syndrome (BD). This study is designed to investigate potential differential capacity of the 3 biomarkers between these disorders. METHODS: A hospital-based case-control study was performed. A total of 29 active CD, 25 IL, 30 ITB and 17 BDpatients were collected. Laboratory parameters were drawn from the first blood test results on admission. RESULTS: In active CD group, the level of CRP was 20.2 ± 4.26 mg/dL, which was statistically lower than IL (59.9 ± 10.8 mg/dL, P < 0.0001). Similarly, the level of ESR reached its lowest point in active CD group (23.8 ± 3.18 mm/hr), compared with 46.6 ± 6.46 mm/hr in IL group (P = 0.0002). CRP showed a possible diagnostic value in differentiation of IL from active CD (odds ratio = 1.028, P = 0.046). CRP also exhibited a superior ability (area under curve [AUC] = 0.821) than ESR (AUC = 0.797) and CRP+ESR (AUC = 0.800) in distinguishing active CD from IL. The optimal cutoff value was 19.7 mg/dL, and the sensitivity and specificity were 62.1% and 96.0%, respectively. CONCLUSIONS: A significant decreased level of CRP and ESR was confirmed in active CD compared with IL. Current study demonstrated a possible differential value of CRP between active CD and IL. Further studies would be performed to validate their clinical significances.
Authors: Julajak Limsrivilai; Andrew B Shreiner; Ananya Pongpaibul; Charlie Laohapand; Rewat Boonanuwat; Nonthalee Pausawasdi; Supot Pongprasobchai; Sathaporn Manatsathit; Peter D R Higgins Journal: Am J Gastroenterol Date: 2017-01-03 Impact factor: 10.864
Authors: Yong Eun Park; Jae Hee Cheon; Jihye Park; Ji Hoon Lee; Hyun Jung Lee; Soo Jung Park; Tae Il Kim; Won Ho Kim Journal: Int J Colorectal Dis Date: 2016-12-27 Impact factor: 2.571
Authors: Helal F Hetta; Alaa A A Mohamed; Asmaa M Zahran; Safaa A Mahran; Marwa My Sayed; Mohamed Ga Saleh; Khaled Abdelazeem; Gaber El-Saber Batiha; Salim Al-Rejaie; Yasir Waheed; Khalid Muhammad; Manal M Hassanien Journal: J Inflamm Res Date: 2021-03-08